Drugs / SCoK
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04813562 | Mar 2021 → Jul 2022 | COVID-19 | Jiangsu Province Centers for Disease Control and Prevention | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SCoK | “a vaccine SCoK against COVID-19 for an efficacy study” PMID 36103390 ↗ Sep 2022 |
| Modality | Vaccine | “a vaccine SCoK against COVID-19” PMID 36103390 ↗ Sep 2022 |
| Route | Intramuscular | “intramuscularly administered 20 or 40 μg vaccine SCoK or placebo” PMID 36103390 ↗ Sep 2022 |